Rezdiffra (Resmetirom) Metabolism and Energy Expenditure

What Is Resmetirom and Why Does the Mechanism Matter for Metabolism?

Resmetirom is a liver-targeted, orally bioavailable small molecule that binds selectively to thyroid hormone receptor beta (THR-beta). Because thyroid hormone is the master regulator of cellular energy balance, a compound that mimics it in the liver, without the arrhythmogenic and bone-loss risks tied to THR-alpha activation, offers a direct route to correcting the metabolic defects that drive MASH.

The FDA granted approval on March 14, 2024, based on histological endpoints from MAESTRO-NASH, making resmetirom the first drug approved for MASH with fibrosis stage F1-F3 (FDA label, 2024).

THR-beta vs. THR-alpha: Why Selectivity Changes Everything

The two thyroid hormone receptor isoforms do very different jobs. THR-beta predominates in the liver, where it governs lipid oxidation, cholesterol synthesis, and mitochondrial biogenesis. THR-alpha predominates in the heart and bone, where unrestricted thyroid agonism accelerates heart rate and accelerates bone resorption.

Resmetirom binds THR-beta with roughly 28-fold greater affinity than THR-alpha (Mulligan et al., 2022, PNAS). That ratio is the pharmacological reason the drug raises hepatic fat oxidation without producing tachycardia or suppressing TSH at therapeutic doses.

Hepatic Uptake and First-Pass Concentration

After oral dosing, resmetirom undergoes extensive first-pass hepatic extraction, so concentrations in the liver far exceed systemic plasma levels. This pharmacokinetic profile amplifies the metabolic signal exactly where MASH pathology lives and limits extrahepatic receptor occupancy.

How Resmetirom Changes Hepatic Fat Oxidation

MASH livers are metabolically congested. Free fatty acids arrive from peripheral lipolysis faster than the organ can oxidize or export them, a state that drives lipotoxic injury, inflammation, and stellate-cell activation. THR-beta agonism addresses that congestion at the enzymatic level.

Mitochondrial Fatty-Acid Oxidation

THR-beta regulates transcription of genes encoding carnitine palmitoyltransferase-1 (CPT-1), the rate-limiting transporter of long-chain fatty acyl groups into the mitochondrial matrix, and multiple enzymes of beta-oxidation. In preclinical hepatocyte models, THR-beta agonism increased CPT-1 activity and raised oxygen consumption rates measurably (Sinha et al., 2020, J Hepatol).

Resmetirom reproduces this effect in human liver. In MAESTRO-NASH, patients on 80 mg showed a 26.1% relative reduction in liver-fat content by MRI-PDFF at week 52 compared with baseline, versus 9.9% in the placebo arm (P<0.001) (Harrison et al., NEJM 2024). That differential reflects net removal of stored triglyceride through oxidative disposal and reduced re-esterification.

Peroxisomal Oxidation and Very-Long-Chain Fatty Acids

Beyond mitochondria, THR-beta also induces peroxisomal acyl-CoA oxidase 1 (ACOX1), which handles very-long-chain fatty acids too large for the mitochondrial matrix. Peroxisomal oxidation is inherently thermogenic because it generates heat rather than ATP at its first enzymatic step. Resmetirom's activation of this pathway contributes to overall hepatic energy dissipation even when mitochondrial capacity is saturated (Sinha et al., 2020, J Hepatol).

Thermogenesis: Hepatic Energy Dissipation in Practical Terms

"Thermogenesis" in the liver context does not mean the patient breaks a sweat. It means the liver converts chemical energy to heat rather than storing it as fat or exporting it as VLDL. This distinction matters clinically because thermogenic pathways reduce lipotoxic substrate without requiring caloric restriction or exercise compliance.

Uncoupling Protein 2 and Proton Leak

THR-beta agonism up-regulates uncoupling protein 2 (UCP2) in hepatocytes. UCP2 inserts a partial proton leak across the inner mitochondrial membrane, dissipating the proton gradient as heat rather than driving ATP synthase (Sinha et al., 2020, J Hepatol). The net effect is substrate oxidation that does not accumulate ATP, a futile cycle that depletes hepatic fat stores without increasing systemic energy expenditure enough to cause measurable weight change.

Whole-Body Resting Energy Expenditure: Is There a Signal?

MAESTRO-NASH was not designed to measure resting energy expenditure (REE) by indirect calorimetry. The trial's primary endpoints were histological. Mean body weight changed minimally across all three arms (placebo, 80 mg, 100 mg) at week 52, suggesting resmetirom's thermogenic effect is compartmentalized to the liver rather than producing a whole-body REE elevation comparable to hyperthyroidism (Harrison et al., NEJM 2024).

That compartmentalization is a feature, not a limitation. Systemic THR-alpha-driven thermogenesis would drive tachycardia, muscle catabolism, and bone loss. The hepatic focus of resmetirom avoids those trade-offs.

HealthRX Clinical Framework: Distinguishing Hepatic from Systemic Thermogenesis

| Parameter | Resmetirom (THR-beta) | Overt Hyperthyroidism (THR-alpha + THR-beta) | |---|---|---| | Hepatic fat oxidation | Markedly increased | Increased | | Resting heart rate | Unchanged at therapeutic doses | Elevated | | TSH suppression | Minimal at 80-100 mg | Marked | | Bone resorption markers | No significant change | Elevated | | REE change | Hepatic compartment only | Whole-body increase | | LDL-C | Reduced ~16% | Reduced |

Lipid and Cholesterol Metabolism: The MAESTRO-NASH Lipid Data

THR-beta governs hepatic cholesterol synthesis and clearance at multiple nodes. It induces LDL receptor expression, CYP7A1 (the rate-limiting enzyme in bile acid synthesis from cholesterol), and suppresses PCSK9 transcription, all of which converge on lower circulating LDL-C.

LDL-C and Apolipoprotein B Reductions

In MAESTRO-NASH, resmetirom 80 mg reduced LDL-C by approximately 16% from baseline at week 52, and apolipoprotein B fell by roughly 14% (Harrison et al., NEJM 2024). These reductions occurred on top of background statin use in a substantial minority of participants, suggesting additive benefit rather than simple redistribution of existing statin effect.

Apolipoprotein B is a more direct marker of atherogenic particle count than LDL-C alone. Reductions in ApoB at this magnitude would typically be considered clinically relevant for cardiovascular risk reduction, though MAESTRO-NASH was not powered for cardiovascular outcomes (Grundy et al., 2019, JACC, AHA/ACC Guideline).

Triglycerides and VLDL Export

MASH livers overproduce VLDL, exporting excess triglyceride into the circulation and contributing to elevated fasting triglycerides. THR-beta activation reduces VLDL secretion by providing an alternative disposal route for hepatic triglyceride through oxidation. In MAESTRO-NASH, fasting triglycerides fell by roughly 10-15% in the active-treatment arms, consistent with reduced de novo lipogenesis and VLDL assembly.

De Novo Lipogenesis Suppression

Thyroid hormone receptor beta regulates SREBP-1c, the master transcription factor for de novo lipogenesis (DNL). In MASH, DNL may account for 26% of hepatic fat content compared with roughly 5% in healthy controls (Lambert et al., 2014, Hepatology). By engaging SREBP-1c indirectly through thyroid hormone signaling, resmetirom may reduce new fat synthesis in parallel with increasing fat oxidation, a dual mechanism that explains the magnitude of liver-fat reduction seen on MRI-PDFF.

MAESTRO-NASH Trial: Primary Histological Endpoints

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1-F3. Patients were randomized 1:1:1 to placebo, resmetirom 80 mg, or resmetirom 100 mg daily. The two co-primary endpoints at 52 weeks were NASH resolution with no worsening of fibrosis, and at least one stage improvement in fibrosis with no worsening of NASH activity score.

NASH Resolution Rates

• Resmetirom 80 mg: 25.9% achieved NASH resolution vs. 9.7% placebo (P<0.001)
• Resmetirom 100 mg: 29.9% achieved NASH resolution vs. 9.7% placebo (P<0.001)

(Harrison et al., NEJM 2024)

Fibrosis Improvement Rates

• Resmetirom 80 mg: 24.2% had at least one stage fibrosis improvement vs. 14.2% placebo (P<0.001)
• Resmetirom 100 mg: 25.9% had at least one stage fibrosis improvement vs. 14.2% placebo (P<0.001)

(Harrison et al., NEJM 2024)

These response rates are modest in absolute terms but represent the first pharmacological demonstration that a drug can reverse MASH histology in a phase 3 trial. The number needed to treat for NASH resolution at 80 mg is approximately 6.

MRI-PDFF as a Metabolic Biomarker

MRI proton-density fat fraction (MRI-PDFF) is the most reproducible non-invasive measure of hepatic steatosis. The 26.1% relative reduction in liver fat at week 52 in the 80 mg arm represents a meaningful metabolic shift. MASH guidelines from the American Association for the Study of Liver Diseases (AASLD) recognize a 30% relative MRI-PDFF reduction as the threshold most predictive of histological response (AASLD Practice Guidance, 2023, Hepatology). Resmetirom approached that threshold; the 100 mg arm crossed it.

Safety Profile: Metabolic and Endocrine Signals

Thyroid Function Tests

Because resmetirom mimics thyroid hormone in the liver, prescribers watch for systemic thyroid axis suppression. In MAESTRO-NASH, free T4, free T3, and TSH remained within normal limits in the active-treatment arms at all measured time points, confirming that hepatic selectivity translated to minimal pituitary feedback suppression (Harrison et al., NEJM 2024).

Cardiovascular Parameters

Heart rate, QTc interval, and blood pressure did not differ significantly between resmetirom and placebo in MAESTRO-NASH, consistent with low THR-alpha engagement at therapeutic doses. The FDA label does not carry a cardiac warning (FDA label, 2024).

Gastrointestinal Events

Nausea and diarrhea were the most common adverse events, reported in roughly 25% and 20% of patients on resmetirom 80 mg versus about 11% and 13% on placebo respectively. These events were mostly mild to moderate and diminished after the first 4-8 weeks. Dose interruption rather than discontinuation managed most cases.

Drug Interactions Relevant to Metabolic Management

Resmetirom is a substrate and mild inhibitor of CYP2C8 and an inhibitor of OATP1B1/1B3 transporters. Co-administration with rosuvastatin raises rosuvastatin AUC by approximately 3-fold. The FDA label caps rosuvastatin at 10 mg daily when combined with resmetirom and recommends similar caution with other OATP1B substrates (FDA label, 2024). Prescribers managing MASH patients on statins for cardiovascular protection must reconcile these interaction risks proactively.

Dosing, Patient Selection, and Monitoring in Practice

Who Qualifies for Resmetirom

The FDA-approved indication is adults with MASH and moderate to advanced liver fibrosis (F2-F3 on METAVIR or equivalent). The prescriber information also references F1 fibrosis with additional risk factors. Body weight drives dose selection: patients weighing <100 kg receive 80 mg once daily; patients weighing 100 kg or more receive 100 mg once daily (FDA label, 2024).

Biopsy confirmation of MASH prior to prescribing is not explicitly required by the label, but clinical guidelines strongly favor histological staging before initiating any anti-fibrotic therapy because non-invasive scores (FIB-4, ELF) still carry meaningful false-positive rates in the F2-F3 range (AASLD Practice Guidance, 2023, Hepatology).

Monitoring Schedule

The HealthRX team recommends the following at minimum:

• Liver enzymes (ALT, AST, alkaline phosphatase) at baseline, 4 weeks, 12 weeks, then every 3-6 months
• Fasting lipid panel at baseline and 12 weeks (LDL-C reductions may necessitate statin dose adjustment)
• Thyroid function tests at baseline; repeat only if symptoms emerge
• MRI-PDFF at baseline and 52 weeks if available, to track metabolic response before next biopsy window

Resmetirom and Concomitant GLP-1 Receptor Agonist Use

Semaglutide and tirzepatide reduce hepatic fat through caloric restriction and reduced substrate delivery. Resmetirom increases hepatic fat oxidation through a receptor-level mechanism. These mechanisms do not overlap, raising the question of additive or complementary benefit. No phase 3 combination trial has reported results as of mid-2025. The MAESTRO-NASH-OLE (open-label extension) is collecting data on patients who also use GLP-1 receptor agonists, but outcomes are not yet published (ClinicalTrials.gov NCT02912260).

Prescribers combining these agents should monitor for excessive ALT elevation and track MRI-PDFF to distinguish additive benefit from overlapping adverse effects.

Resmetirom in the Broader MASH Treatment Field

Before March 2024, no pharmacological agent had regulatory approval for MASH. Weight-loss interventions (lifestyle modification targeting 7-10% body weight loss, bariatric surgery in eligible patients) remained the only evidence-based treatments. The American Association for the Study of Liver Diseases stated in its 2023 guidance document: "No pharmacological therapy is currently approved for MASH; treatment rests on lifestyle modification and management of metabolic comorbidities" (AASLD Practice Guidance, 2023, Hepatology). Resmetirom changed that statement.

Obeticholic acid, a farnesoid X receptor (FXR) agonist, showed fibrosis improvement in the REGENERATE trial but failed to meet its primary endpoint at interim analysis and carries a black-box warning for liver decompensation in patients with cirrhosis. Lanifibranor (PPAR pan-agonist) met both co-primary histological endpoints in the NATIVE trial but does not yet have FDA approval (Francque et al., NEJM 2021).

Resmetirom's approval therefore stands alone in the approved space, though the pipeline behind it is active.

What Clinicians Ask Most: Practical Questions Answered

The questions below address real prescribing uncertainty. Resmetirom's novel mechanism generates a predictable set of questions from endocrinologists, hepatologists, and internists managing metabolic disease.

Does resmetirom cause weight loss? Weight loss was not a primary or secondary endpoint in MAESTRO-NASH and mean weight change across arms was minimal. Resmetirom is not indicated for weight management.

Can resmetirom replace a statin? No. Although it reduces LDL-C by roughly 16%, this effect does not substitute for guideline-directed statin therapy in patients with established cardiovascular disease or high 10-year ASCVD risk (Grundy et al., 2019, JACC).

Does it work in F4 (cirrhosis)? MAESTRO-NASH excluded F4 patients. Resmetirom should not be used in decompensated cirrhosis. Data in compensated cirrhosis (F4) are limited.